• Surgicure Technologies

  Participated · Seed · Mar 2025

  Surgicure Technologies develops medical devices to improve airway management and patient safety, with a patented flagship product called the Horseshoe. The Horseshoe is designed to provide more reliable endotracheal (ET) tube securement, prevent facial pressure injuries, and enable more effective oral care. The technology was originally invented by army respiratory therapists and redesigned by founder Irena King. Surgicure targets clinical settings such as critical care, burn/trauma care, and patient evacuation or transport where improved securement and streamlined workflows can reduce adverse events. The company is female-owned and was founded in 2019; it is working to commercialize its solution and scale adoption across diverse medical environments. Surgicure recently closed a financing round to support commercialization efforts.

• Aware Health

  Participated · Seed · Oct 2024

  Aware Health provides on-demand, direct-to-employer musculoskeletal care using proprietary diagnostic algorithms and virtual same-day clinician access to reduce unnecessary imaging and surgeries. Employers subscribe on a per-member basis so employees and their families receive early, upstream MSK intervention aimed at faster recovery and sustained productivity. The company reports a peer-reviewed 59% reduction in orthopedic healthcare claims and that 95% of patients who initially planned surgery avoided it, with clients seeing an average 6.19x lifetime healthcare cost ROI. Aware Health emphasizes algorithm-guided virtual diagnosis to improve PT diagnostic accuracy versus competitors focused on motion-sensor exercise form. With the new funding, the company plans to build out AI models, a patient and provider engagement platform, and comprehensive employer dashboards. Aware Health was founded in 2020 and is based in San Francisco, CA.

• DeepLook Medical

  Participated · Equity · Feb 2024

  DeepLook Medical’s flagship product, DL Precise™, is an AI-powered software that uses shape-recognition algorithms to visualize, measure, and segment abnormal growths in dense breast tissue. The company positions DL Precise™ as a tool to improve accuracy in detecting and assessing suspicious lesions, with the potential to enhance early cancer detection and patient outcomes. DeepLook says its technology is the first in a series of products built on its unique shape-recognition software and leveraged alongside complementary AI advances and patented technology. The company plans to use newly raised capital to further commercialize its technology with current and new partners, explore applications in additional imaging modalities, and broaden its global presence. DeepLook emphasizes improving physician diagnosis and treatment decisions across oncology through clearer tumor morphology delineation. The press release highlights Xcellerant’s support and strategic involvement as part of its commercialization efforts. DeepLook Medical, led by CEO Marissa Fayer and based in New Haven, Connecticut, develops AI software to improve visualization of suspicious masses in dense breasts. Its flagship product, DL Precise, is an FDA-cleared shape-recognition platform that overlays onto existing imaging screens to provide one-click measurement, segmentation, and visualization. DL Precise delineates tumor morphology using a single-click deterministic algorithm and is compatible with mammography, ultrasound, CT, and MRI. The product has entered the commercial market through partnerships with Barco, Blackford, Tempus, and Radical Imaging. DeepLook plans to use the $1.7M funding to hire talent, advance next-generation products, expand sales and partnerships, support additional clinical research and publications, and extend global IP and regulatory protections and clearances. The company is also leveraging complementary AI advances to enhance the reach and impact of its patented technology.

• Owl's Brew

  Participated · Series A · Sep 2021

  Owl’s Brew produces Boozy Tea, a line of hard tea seltzers crafted with real ingredients and marketed with commitments to no artificial flavors, no natural flavors, no animal byproducts, no parabens, and no sulfites. The product lineup includes six styles such as Matcha & Pineapple, English Breakfast & Lemon, Darjeeling & Hibiscus, White Tea & Watermelon, Jasmine & Blueberry, and a seasonal Spiced Chai & Cranberry. The company is led by tea experts Jennie Ripps and Maria Littlefield and is female-founded. Its distribution spans major retailers nationwide including Trader Joe’s, Whole Foods, Publix, Total Wine, HEB, Sprouts, and GoPuff. Since launch the company reports 918% growth, expanding from 10 to 18 U.S. markets and securing national mandates from several large retailers. Owl’s Brew intends to use new funding to expand distribution, invest in marketing, and grow the team. Owl’s Brew was founded by Jennie Ripps and Maria Littlefield and launched Owl’s Brew Mixers in 2013. The company makes non-alcoholic tea-based cocktail mixers and in late 2016 introduced Owl’s Brew Radler, the first blend of tea and beer. Radler SKUs include The Blondie, Wicked Watermelon and That’s My JAM, each at 3.8% ABV and composed of roughly 60% craft beer and 40% fresh-brewed tea. The mixers are fresh-brewed from organic tea bases and the lineup has earned awards including a Sofi Award and BevNet recognition; the founders have also received Forbes and Specialty Food mentions. Distribution for Radler has rolled out across the eastern U.S. with availability in many on- and off-premise locations and nationwide shipping for mixers online. The company plans further geographic expansion to the west coast and nationwide.

No current team members are available.